Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H57N11O9.2C2H4O2 |
| Molecular Weight | 871.9779 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CC(O)=O.C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(O)=O
InChI
InChIKey=VHEHIIUPYDNNTE-UXAXJNOXSA-N
InChI=1S/C33H57N11O9.2C2H4O2/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53;2*1-2(3)4/h19-24,26,45H,2-18,34-35H2,1H3,(H,39,47)(H,40,48)(H,41,49)(H,52,53)(H4,36,37,38);2*1H3,(H,3,4)/t19-,20+,21+,22+,23+,24+,26+;;/m1../s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. | 2001 Apr |
|
| [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. | 2001 May-Jun |
|
| Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. | 2002 Feb |
|
| [Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress]. | 2002 Jun |
|
| [Optimizing action of synthetic peptide Selank on active avoidance conditioning test in rats]. | 2002 Sep-Oct |
|
| Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. | 2003 Nov |
|
| The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. | 2003 Sep |
|
| A new property of the synthetic anxiolytic Selank and its derivatives. | 2004 Jul-Aug |
|
| [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. | 2004 May-Jun |
|
| Seasonal effects of Selank on the behavior of hibernating animals. | 2005 Dec |
|
| [Effect of new synthetic anxiolytic selank on gastric wall blood flow and mesenteryc lymphatic vessels contractility in anesthetized rats]. | 2005 Feb |
|
| [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]. | 2005 Jul-Aug |
|
| [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. | 2006 Mar-Apr |
|
| [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]. | 2006 Mar-Apr |
|
| Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. | 2006 Nov |
|
| [Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia]. | 2006 Nov |
|
| Selank and its metabolites maintain homeostasis in the gastric mucosa. | 2007 Jan |
|
| Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. | 2007 Nov |
|
| [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. | 2008 |
|
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. | 2008 |
|
| Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia. | 2008 Feb |
|
| Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. | 2008 Jul-Aug |
|
| [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. | 2008 Mar-Apr |
|
| [Compensatory effect of selank on the mnestic functions disturbed by neurotoxic damage of the noradrenergic system of the rat brain]. | 2008 Mar-Apr |
|
| [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]. | 2008 May-Jun |
|
| [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]. | 2008 Sep-Oct |
|
| [Experimental hemorrhagic stroke: the study of neuropeptides (MIF, selank) in the intraperitoneal injection]. | 2009 |
|
| [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. | 2009 Jul-Aug |
|
| [Antiviral activity of immunomodulator Selank in experimental influenza infection]. | 2009 Sep-Oct |
|
| [Experimental optimization of learning and memory processes by selank]. | 2010 Aug |
|
| Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank. | 2010 Jan-Feb |
|
| Antiviral properties of structural fragments of the peptide Selank. | 2010 Mar-Apr |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
155804769
Created by
admin on Sat Dec 16 14:53:22 GMT 2023 , Edited by admin on Sat Dec 16 14:53:22 GMT 2023
|
PRIMARY | PUBCHEM | ||
|
Q94Z9E92UU
Created by
admin on Sat Dec 16 14:53:22 GMT 2023 , Edited by admin on Sat Dec 16 14:53:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
